This paper describes the consequences of alaninescanning mutagenesis on 28 positions of the second epidermal growth factor (EGF-2) domain of factor IX. We identified four positions of Gln 97 , Phe 98 , Tyr 115 , and Leu 117 that are critical for secretion of factor IX. Of the remaining mutations, 4 mutants (V86A, E113A, K122A, and S123A) are as active as wild-type factor IX (IXwt); 16 (D85A, K100A, N101A, D104A, N105A, R116A, E119A, T87A, I90A, K91A, R94A, E96A, S102A, K106A, T112A, and N120A) retain reduced but detectable activity, and 4 (N89A, N92A, G93A, and V107A) are nearly inert in the clotting assay. Both factor XIa and the factor VIIa-tissue factor complex effectively catalyzed the activation of these mutants except N89A. The mutant V107A failed to form the factor tenase complex with factor VIIIa because of a 35-fold increase in K d . The mutants N89A and N92A did not compete with factor IXwt for factor VIIIa binding, and G93A exhibited a 6-fold increase in K i values in the competitive binding assay. It appears that mutations at these positions have significantly affected the interaction between factor IX and factor VIIIa, although other mutations had little effect on the binding of factor IX to factor VIIIa. Mutations in two regions, Thr 87 -Gly 93 and Asn 101 -Val 107 , significantly increased the K m value of factor IXa (2-10-fold) in cleavage of factor X in the absence of factor VIIIa. In the presence of factor VIIIa, the catalytic efficiency of each mutant toward factor X paralleled its clotting activity. Briefly, we propose two relatively distinctive functions of factor IX for two adjacent regions in the EGF-2 domain; the first loop region (residues 89 -94) is involved with the binding of its cofactor, factor VIIIa, and the third loop with connected ␤-sheets (residues 102-108) is involved in the proper binding to the substrate, factor X.
Blood coagulation factor IX, a vitamin K-dependent serine protease precursor, plays a critical role in regulation and amplification of the blood coagulation in the intrinsic clotting cascade. The clotting cascade consists of series of serine proteases, in which each protease activates its downstream zymogen in highly specific manners (1, 2) . The activation of factor IX by proteolytic cleavages of two peptide bonds by factor XIa or by the factor VIIa-tissue factor (VIIa-TF) 1 complex results in a catalytically active two-chain molecule of factor IXa (3) (4) (5) . Factor IXa converts zymogen factor X into factor Xa, which is responsible for the activation of prothrombin to thrombin. Generation of factor Xa by factor IXa requires factor VIIIa, the only macromolecular protein cofactor identified for factor IXa (6, 7) . The interaction between factor IXa and factor VIIIa requires both factors to be activated. Defects in both proteins are linked to hemophilia.
The zymogen form of factor IX has five structural domains as follows: the Gla domain, two EGF-like domains, the activation peptide, and the catalytic domain (8) . Upon activation, the activation peptide is released from factor IXa. A number of experiments have indicated that a few regions in the catalytic domain (residues 301-303 and 333-339) may confer factor VIIIa binding (9 -11) . Furthermore, two EGF domains have long been proposed to be critical for the interactions between factor IX and factor VIIIa (12) (13) (14) (15) . The EGF-2 domain of factor IX contains 43 residues (Asp 85 -Ala 127 , factor IX numbering system) and is highly conserved among different organisms, with 80 -85% amino acid sequence identity. Furthermore, the EGF-2 domains among factors VII, IX, X, and protein C share 30 -50% sequence homology (16) . Domain swapping experiments showed that the chimeric recombinant factor IX, in which the EGF-1 domain was replaced by that of factor X or factor VII, retained full factor IXa activity, indicating that the EGF-1 domain does not contribute to factor VIIIa binding in a factor IX-specific manner (13, 17) . However, substituting two EGF domains with that of factor X (factor IX Xegf1ϩ2 ) the chimeric factor IX lost almost all of its clotting activity (13) . This strongly suggests that the EGF-2 domain is critical for factor IX-specific function. In other studies using the chimeric recombinant factor IX Xegf2 (factor IX with the EGF-2 domain from factor X), it is suggested that the EGF-2 domain is required for the assembly of the functional intrinsic factor IXa-factor VIIIa (factor tenase) complex on the surfaces of the activated platelets but is not directly involved in the interaction between factor IXa and factor VIIIa (18, 19) .
The EGF-2 domain is composed of five ␤-strands and four ␤-hairpin loops based on the crystal structure of porcine factor IXa (14) . Mutations at residues located along the concave surface of factor IXa (such as residues Ile 90 , Asn 92 , and Arg 94 ) appear to be associated with hemophilia, indicating functional significance of this region (14, 20) . Arg 94 is involved in the formation of a salt bridge with residue Glu 78 of the EGF-1 domain, which may be critical for the interaction with factor VIIIa (21) . Glu 78 is conserved in the EGF-1 domain of factors IX and X, and therefore, replacing only the EGF-1 of factor IX with that of factor X might not influence the stability of the salt bridge. In contrast, changing both EGF domains between factor IX and factor X would eliminate the salt bridge and perturb the integrity between these two EGF domains, and consequently affect the activity of factor IX. (14) . When the hydrophobic region of residues Lys 106 -Val 108 was replaced by the corresponding site of factor VII, the mutation caused a dramatic decrease in factor IXa activity toward factor X both in the absence and the presence of factor VIIIa (22) . This suggests that the decrease of the factor IX activity can be attributed to a defect in the interaction of factor IX and its substrate, factor X (22) . The study suggested that the proper orientation and interaction of the EGF-1 and -2 domains are crucial for substrate binding. Whether and how the EGF-1 and -2 interdomain interactions affect the bindings of factor VIIIa and factor X remains to be determined.
In this study, we conducted an extensive alanine-scanning mutagenesis of the EGF-2 domain of factor IXa spanning residues 85 and 125 in order to identify the EGF-2 region that interacts with the cofactor and substrates of factor IX. We provide an analysis of the functional roles of the aforementioned salt bridge and the hydrophobic interactions that link the two EGF domains of factor IX.
EXPEIMENTAL PROCEDURES
Materials-All the restriction endonucleases and polymerases were obtained from New England Biolabs, Inc. (Beverly, MA). Geneticin (G418) was from Invitrogen. Factor IX-deficient plasma, phosphatidylcholine (PC), and phosphatidylserine (PS) were purchased from Sigma. Human factor XIa, factor Xa, and factor X were purchased from Enzyme Research Laboratory (South Bend, IN). Preparations of tissue factor, factor VII, factor VIIa, and phospholipids were described previously (23) . Polyclonal anti-factor IX antibodies were prepared by immunization of rabbits with plasma-derived factor IX as described previously (24) . Monoclonal anti-factor IX antibodies (A1, A5, and A7, see Ref. 25) were provided by Dr. Kenneth Smith (Emory University, Atlanta, GA). Spectrozyme FXa and spectrozyme FIXa were purchased from American Diagnostica (Greenwich, CT). Insulin/transferrin/sodium selenite (ITS) supplements used in serum-free media were from Roche Molecular Biochemicals. A V max microtiter plate reader (Molecular Devices Corp., Menlo Park, CA) equipped with a thermal controller was used for all spectrophotometric assays. QAE-Sephadex and Resource Q were from Amersham Biosciences. DEGR-CK was a product of Calbiochem.
In Vitro Mutagenesis, Expression of Mutant Factor IX, and Protein Purification-Mutagenesis was performed by the PCR-based method following the manufacturer's instructions (QuikChange site-directed mutagenesis kit, Stratagene, Boston). Pairs of specific primers were synthesized to create codons for alanine at individual positions within amino acid residues 85-127. The altered cDNA was fully sequenced and subcloned into pCR3 TM -Uni (Invitrogen) for expression in human 293 cells under the control of the cytomegalovirus promoter (26) . Transfection and identification of cell clones expressing factor IX were performed as described previously (24) . The cultured supernatant was collected and stored at Ϫ20°C for further analysis.
Protein Purification, SDS-PAGE, Immunoblotting, and Clotting Assays-Recombinant factor IX was purified by a method similar to Yan et al. (27) . Briefly, 1 liter of the cultured supernatant (containing 1-4 mg of factor IX) was adjusted to 2 mM benzamidine and 5 mM EDTA and subjected to centrifugation at 4350 rpm (Sorvall RC-3C Plus, DuPont) for 45 min at 4°C. After removal of the cell debris, the supernatant was passed through a QAE-Sephadex A50 column (30 ml in 2.5 ϫ 20 cm) equilibrated with TBS (20 mM Tris-Cl, pH 7.5, and 100 mM NaCl). After washing the column with 1 liter of TBS and 1 mM benzamidine, factor IX was eluted with a gradient of 0 -30 mM CaCl 2 in TBS and 1 mM benzamidine. Fractions containing factor IX were identified by ELISA as described previously (13, 28) , pooled, dialyzed against 100-fold excess volumes of 50 mM Tris-Cl, pH 7.5, and filtered through a 0.22-m syringe filter (Nalge Nunc International, New York). Approximately 100 ml of the QAE-eluent was loaded on to a Resource Q column (1 ml, Akta FPLC purifier, Amersham Biosciences). After washing with 10 ml of 50 mM Tris-Cl, pH 7.5, the column was eluted with a gradient of NaCl (0 -1 M) in 50 mM Tris-Cl, pH 7.5. Factor IX was eluted at fractions of ϳ350 mM NaCl. Purified proteins (0.2-1 mg) were verified to be Ͼ95% purity by SDS-PAGE followed by staining with silver nitrate (Silver Stain kit, Bio-Rad). The protein assay kit (Bio-Rad) modified from the Bradford method (29) and the ELISA method using monoclonal antibodies recognizing human factor IX were used to measure the concentration of purified factor IX proteins as described previously (24, 26) . By using factor IX-deficient plasma, clotting activity was measured by the one-stage aPTT clotting assay following the manufacturer's instructions (Pathromtin, Behring, Germany) as described previously (24, 28) . Pooled plasmas of at least 20 healthy individuals were used in parallel experiments to prepare standard curves for calculation of activities and protein concentrations (by ELISA) of related clotting factors (28) . The specific activity of the purified recombinant wild-type factor IX was comparable with that of plasma-derived factor IX (26) .
Activation by Factor XIa and Factor VII-TF Complex and the Preparation of Factor
IXa-Activation of factor IX by factor XIa and VIIa-TF was performed as described previously (24, 26) . The VIIa-TF complex was prepared as described previously (23, 26) . Purified wild-type and mutant factor IX proteins (1.8 M) were incubated at 37°C with factor XIa (9 nM) and VIIa-TF complex (36 nM). The reaction products of both experiments were analyzed at timed intervals by SDS-PAGE followed by silver staining. To determine the rate of factor IX hydrolysis by the VIIa-TF complex, a two-step kinetic assay was performed in that IXwt and N89A (1.8 M) were incubated with VIIa-TF (18 nM) in 50 l of TBS/Ca/bovine serum albumin (20 mM Tris-Cl, pH 7.5, 100 mM NaCl, 5 mM CaCl 2 , 0.01% bovine serum albumin) at 37°C. The reaction mixtures were withdrawn at different time points (5-60 min) and stopped by addition of 10 l of 12 mM EDTA. The factor IXa activity generated by the VIIa-TF complex at each time point was measured by the addition of 40 l of Spectrozyme FIXa at a final concentration of 4 mM. Hydrolysis was monitored at 405 nm and 37°C for 1 h, and the initial rates (mOD/min) for the sampled mixtures of wild-type factor IX and N89A were recorded and plotted versus the durations of cleavage by VIIa-TF. The slope of each curve represents the efficiency of the cleavage of wild-type factor IX and N89A, respectively, by VIIa-TF.
The activated wild-type and mutant factor IXa (1.8 M) was prepared by incubation of the purified proteins with factor XIa (9 nM) at 37°C for 2 h. Complete activation of factor IX to factor IXa was monitored by SDS-PAGE and silver stain. The concentration of the generated wildtype factor IXa was also determined by titration with antithrombin III with the assumption that 1 mol of factor IXa is inhibited by 1 mol of antithrombin III (30) . The amount of antithrombin III required to completely inhibit the activated factor IXa activity toward factor X was assumed to be the concentration of factor IXa, which correlated to that determined by SDS-PAGE.
Activation of Factor X by Factor IXa in the Absence and Presence of Factor VIIIa-The activity of wild-type and mutant factor IXa toward factor X was monitored kinetically through the hydrolysis of Spectrozyme FXa by factor Xa in the absence and presence of factor VIIIa as described previously (24, 26) . Final concentrations were factor IXa, 10 nM, PCPS, 100 M, Spectrozyme FXa, 0.5 mM, and factor X, 0.025-1 M. The amount of factor Xa generated was computed from a standard curve derived by the hydrolysis of Spectrozyme FXa with factor Xa (Enzyme Research Laboratories) prepared by immobilized Russell's viper venom. The factor Xa preparation was fully active as analyzed by an active site-specific fluorogenic substrate (31), 4-methylumbelliferyl p-guanidinobenzoate (Fluka), as described before (32), in a Hitachi 850 fluorescent spectrophotometer. The factor IXa activity was then calcu-lated according to an active site as described previously (24, 30) by the following equation: A 405 ϭ a t 2 ϩ b t ϩ c (30) . Factor VIIIa was prepared freshly by incubation with thrombin as described previously (24, 33) . To analyze the interaction of factor IXa with factor X in the presence of factor VIIIa, 25 l of the factor VIIIa preparation was mixed with an equal volume of factor IXa preincubated with PCPS in TBS/Ca/bovine serum albumin. The mixture was used to form the intrinsic factor tenase complex, and its activity toward factor X was subsequently analyzed kinetically by adding 50 l of a reaction mixture containing PCPS and Spectrozyme FXa. The final concentrations are as follows: for wild-type or mutant factor IXa, 0.25 nM; factor VIIIa, 0.4 nM; PCPS, 100 M; factor X, 0 -200 nM; and Spectrozyme FXa, 0.5 mM. The factor IXa activity was calculated as described above.
Binding of Factor IXa to Factor VIIIa-Binding experiments were performed by monitoring the intrinsic factor tenase activity at limiting concentrations of factor VIIIa as described previously (26, 33) . Freshly prepared factor VIIIa (1.6 nM, 25 l) was incubated with 25 l of different concentrations of wild-type or mutant factor IXa at room temperature for 5 min to form a factor tenase complex. Activity of the resultant complex was then measured as described above. The total volume of the reaction mixtures was 100 l, and the final concentrations are as follows: factor VIIIa, 0.5 nM; PCPS, 100 M; factor X, 100 nM; Spectrozyme FXa, 0.5 mM; and factor IXa, 0 -40 nM. The reaction was measured at 37°C kinetically on a microtiter plate reader. Experiments were performed in duplicate for 3-5 independent reactions, and curves were fitted using all data points. The K d values were derived as previously described (26, 34, 35) .
Preparation of the Active Site-modified Wild-type and Mutant Factor IXa-Wild-type and mutant factor IXa (N89A, N92A, and G93A) were inactivated with DEGR-CK as described previously (33, 36, 37) . Recombinant factor IXa, at a concentration of 1 M in 50 l of TBS, was incubated with a 3-fold molar excess of DEGR-CK for 7 h at room temperature and then for 17 h at 4°C. Then wild-type and mutant factor IXa (DEGR-IXa) were separated from excessive DEGR-CK by extensive dialysis against TBS at 4°C. The remaining enzymatic activity of the wild-type factor IXa was measured by aPTT clotting test and found to contain less than 0.05% of untreated wild-type factor IXa. The remaining activity of the mutant factor IXa (N89A, N92A, and G93A) was measured to determine whether their amidolytic activities toward Spectrozyme FIXa were Ͻ0.1% of their uninhibited counterparts.
Inhibition of Factor X Activation by the Intrinsic Factor Tenase Complex with DEGR-IXa-Competition experiments were carried out by incubating wild-type factor IXa and factor VIIIa with different concentrations of wild-type and mutant DEGR-IXa as competitors at room temperature for 5 min. The residual factor tenase complex activity was measured for the activity toward factor X as described above. Final concentrations are as follows: factor VIIIa, 0.55 nM; PCPS, 100 M; factor X, 100 nM; Spectrozyme FXa, 0.5 mM; wild-type factor IXa, 0.05 nM; and wild-type or mutant DEGR-IXa, 0 -50 nM. The relative rate of factor Xa generation in the presence of each DEGR-IXa was used to calculate K i according to Equation 1 as described by Larson et al. (33) .
RESULTS

Expression and Specific Clotting Activities of Factor IX Variants-
In order to preserve disulfide bonds, cysteine residues (positions 88, 95, 99, 109, 111, and 124) were not substituted. Residues 110 and 114 were also omitted from this study because the missense mutations at these positions were reported to cause hemophilia B with little antigen levels. Residues 103 and 118 are alanine in factor IX; thus they were not investigated. Recombinant factor IX mutants were designated as D85A, V86A, etc. respectively. When expressed in stably transfected cells, all mutants except Q97A, F98A, Y115A, and L117A, were secreted at levels comparable with wild-type factor IX (IXwt). The secreted factor IX mutants reacted with a polyclonal antibody and three different monoclonal anti-factor IX antibodies. At least one of the antibodies is known to be conformational specific (25) indicating that the alanine replacements at these positions did not alter the global structure of factor IX. Immunostaining showed that Q97A, F98A, Y115A, and L117A were accumulated inside the cells (data not shown), suggesting that these substitutions disrupted the secretion of factor IX. These four mutants were not characterized further in subsequent experiments.
The specific clotting activities of the 24 secreted alanine mutants are summarized in Fig. 1 . One mutant, V86A, was found two times more active than factor IXwt. Three (E113A, K122A, and S123A) were as active as factor IXwt. In contrast, N89A, N92A, G93A, and V107A had minimal clotting activities. Of the remaining 16 mutants, 7 (D85A, K100A, N101A, D104A, N105A, R116A, and E119A) had 46 -75% IXwt activity, and the other 9 (T87A, I90A, K91A, R94A, E96A, S102A, K106A, T112A, and N120A) showed decreased activity to 7-37%.
Activation of Factor IX Variants by Factor XIa and the Factor VIIa-TF Complex-All variants, with the exception of N89A, were activated efficiently by factor XIa and the factor VIIa-TF complex. The cleavage of N89A by factor XIa was as efficient as factor IXwt, but its cleavage by the factor VIIa-TF complex was FIG. 1. Specific clotting activities of the alanine-scanned EGF-2 mutants. The protein levels of each factor IX mutant were determined by ELISA using three monoclonal anti-factor IX antibodies (see "Experimental Procedures"). Their clotting activities were determined by aPTT assays using factor IX-deficient plasma (Parthromtin, Behring Diagnostics, Inc., Somerville, NJ). For both ELISA and aPTT assays, standard curves were derived using serial dilutions of pooled normal plasma in parallel experiments. Specific activities are factor IX levels measured by aPTT divided by the factor IX levels measured by ELISA, and expressed as percentage of pooled normal plasma factor IX. Shown here are mean values of duplicates in multiple experiments. The specific activity of factor IXwt is ϳ100 Ϯ 3.1%. The structure is taken from Protein Data Bank code 1pfx (www.rcsb.org). Buried residues (GETAREA (www.scsb.utmb.edu/getarea)) with water-accessible areas less than 30 slightly ineffective (Fig. 2, panels A and B) . Kinetic analysis also showed that the efficiency of N89A hydrolysis by the factor VIIa-TF complex was two times lower than that of factor IXwt (Fig. 2, panel C) . Activated N89A hydrolyzed peptide substrates as efficiently as wild-type factor IXa (data not shown).
These results indicate that position Asn 89 played a role in the recognition of factor IX by the factor VIIa-TF. However, the effect is very small and is not sufficient to explain the loss of the clotting activity of N89A.
Activation of Factor X in the Absence and Presence of Factor VIIIa-The proteolytic activities of the mutated factor IXa toward macromolecular substrate, factor X, were evaluated in the absence and the presence of its cofactor, factor VIIIa. In the absence of factor VIIIa, the alanine mutations in two clustered regions resulted in decreased activity for factor X. One region contains mutants T87A-G93A, and the other contains S102A-V107A, and both had nearly 2-10-fold elevation of K m , whereas their k cat values were similar to the IXwts (Table I) In the presence of factor VIIIa, the catalytic efficiency of each mutant was measured as a complete intrinsic factor tenase. As shown in Table II , most of the mutants exhibited catalytic efficiencies (k cat /K m ) that parallel their clotting activities (Fig.  1) . Factor VIIIa failed to enhance the catalytic rates of the mutants N89A, N92A, and G93A. In contrast, there were eight mutants (V86A, T87A, K100A, N105A, E113A, E119A, K122A, and S123A) with significant increase of k cat (Table I ). The increased clotting activity with V86A is due to the increase in catalytic efficiency upon factor VIIIa binding. The slightly decreased clotting activity found with K100A, N105A, and E119A is due to increased K m (Table I) .
Factor IXa Binding to Factor VIIIa-To investigate the difference in the enhancement of factor IXa activity by factor VIIIa, the binding of the mutant factors IXas to factor VIIIa was examined. Based on the assumption that the intrinsic factor tenase activity is proportional to the concentration of the factor IXa-factor VIIIa complex, the binding affinity was determined by monitoring factor X activation. Table II shows the apparent dissociation constant (K d ) of each mutant factor IXa for factor VIIIa. We found that the K d values for most of the mutants were comparable with that of the activated factor IXwt (K d ϭ 1.1 nM), suggesting that these mutants bound factor VIIIa as efficiently as factor IXwt. T87A and T112A have slightly increased K d values (3-4.5-fold) and V107A has a 35-fold increased K d value, indicating that the decreased clotting activities of these mutants may be caused by the decreased affinities for factor VIIIa Because N89A, N92A, and G93A exhibited extremely low activities in the presence of factor VIIIa, competition experiments were designed to determine the affinity for factor VIIIa for these variants. In this assay, increasing concentrations of inactivated factor IXa variants were added to compete with activated factor IXwt for factor VIIIa binding. First, activated factor IXwt was tested to evaluate the assay. As shown in Fig.  3 , wild-type DEGR-IXa inhibited the binding of normal factor IXa with a K i of 0.95 nM that is very consistent with the K d value estimated from the kinetic assay in the previous section. DEGR-IXaG93A was partially effective in competing with normal factor IXa for binding factor VIIIa (K i ϭ 5.7 nM), and neither DEGR-IXaN89A nor DEGR-IXaN92A showed effective competition. It appears that alanine substitutions at positions 89, 92, and 93 significantly altered the interaction between factor IXa and factor VIIIa. In addition, the estimated factor VIIIa binding for G93A is considerably tighter than that of V107A (K d ϭ 35.8 nM); however, the enhancement of factor IXa activity by factor VIIIa is undetectable with G93A. This may indicate that the residue is not only significant for factor VIIIa binding but is also important for the conformational change that occurs upon factor VIIIa binding and normally leads to increased k cat . 
DISCUSSION
In this study, the functional roles of 28 residues in the EGF-2 domain of factor IX were characterized by alanine-scanning mutagenesis. To our knowledge, this is one of the most extensive studies ever performed on the EGF-like domains. We have shown that mutations at four positions, Asn 89 , Asn 92 , Gly 93 , and Val 107 , eliminate the clotting function of factor IX. Through competition experiments, we further demonstrated that the loss of the clotting activity was probably due to defects in factor VIIIa binding. As shown in Fig. 4 , Arg 94 forms a salt bridge to Glu 78 of the EGF-1 domain. It has been proposed that the salt bridge linking the two EGF domains is required for factor VIIIa binding (21) . Our kinetic and competition experiments (Table I,  Table II , and Fig. 3 Fig. 4 . The crystal structure of the factor VIIa-TF complex revealed that the TF-binding sites are distributed among the multiple domains of factor VII (38) (39) . Thus, the locations of the cofactor-binding sites in the EGF-2 domains in factor VII and factor IX are similar. However, the significant contribution of the interaction between the EGF-2 domain and cofactor to the overall binding energy appears to be unique to factor IX. The side chain of Asn 89 is exposed to solvent and does not interact with any residue within factor IX ( Fig. 1 and see Ref. 14) . Asn 89 may directly provide a hydrogen bond to factor VIIIa and support Fig. 3 is 5.7 Ϯ 0.27 nM. More than three independent experiments were performed, and the mean values of the rate of factor Xa generation at each factor IXa concentration are shown. The B max for wild-type factor IXa is 17.52 Ϯ 1.23 nM factor Xa/min and for mutant factor IXaV107A is 1.8 Ϯ 0.25 nM factor Xa/min.
